JP2022535894A - 放出調節製剤およびその使用 - Google Patents

放出調節製剤およびその使用 Download PDF

Info

Publication number
JP2022535894A
JP2022535894A JP2021572445A JP2021572445A JP2022535894A JP 2022535894 A JP2022535894 A JP 2022535894A JP 2021572445 A JP2021572445 A JP 2021572445A JP 2021572445 A JP2021572445 A JP 2021572445A JP 2022535894 A JP2022535894 A JP 2022535894A
Authority
JP
Japan
Prior art keywords
amisulpride
dosage form
oral dosage
solid oral
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021572445A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022535894A5 (https=
JPWO2020247603A5 (https=
Inventor
拓海 淺田
アール ガルッピ，ジェラルド
キャボット ホプキンス，セス
芽含 丸山
トゥーンスワン，シリポーン
悠貴 対馬
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma America Inc
Original Assignee
Sunovion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunovion Pharmaceuticals Inc filed Critical Sunovion Pharmaceuticals Inc
Publication of JP2022535894A publication Critical patent/JP2022535894A/ja
Publication of JP2022535894A5 publication Critical patent/JP2022535894A5/ja
Publication of JPWO2020247603A5 publication Critical patent/JPWO2020247603A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2021572445A 2019-06-04 2020-06-04 放出調節製剤およびその使用 Pending JP2022535894A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962856863P 2019-06-04 2019-06-04
US62/856,863 2019-06-04
US202063011584P 2020-04-17 2020-04-17
US63/011,584 2020-04-17
PCT/US2020/036084 WO2020247603A1 (en) 2019-06-04 2020-06-04 Modified release formulations and uses thereof

Publications (3)

Publication Number Publication Date
JP2022535894A true JP2022535894A (ja) 2022-08-10
JP2022535894A5 JP2022535894A5 (https=) 2023-06-13
JPWO2020247603A5 JPWO2020247603A5 (https=) 2023-06-13

Family

ID=73652146

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021572445A Pending JP2022535894A (ja) 2019-06-04 2020-06-04 放出調節製剤およびその使用

Country Status (4)

Country Link
US (1) US20220323409A1 (https=)
EP (1) EP3980008A4 (https=)
JP (1) JP2022535894A (https=)
WO (1) WO2020247603A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018378348B2 (en) 2017-12-05 2024-09-19 Sunovion Pharmaceuticals Inc. Crystal forms and production methods thereof
CA3084953A1 (en) 2017-12-05 2019-06-13 Sunovion Pharmaceuticals Inc. Nonracemic mixtures and uses thereof
AU2020286441A1 (en) 2019-06-04 2022-01-06 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof
CN115487161B (zh) * 2022-11-18 2023-03-03 山东则正医药技术有限公司 一种氨磺必利片的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001523241A (ja) * 1997-04-18 2001-11-20 サノフィ−サンテラボ 胃滞留性医薬組成物
WO2010023690A2 (en) * 2008-08-28 2010-03-04 Torrent Pharmaceuticals Ltd. Prolonged release formulation of amisulpride

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201004020D0 (en) * 2010-03-11 2010-04-21 Acacia Pharma Ltd New therapeutic use
US10441544B2 (en) * 2017-10-10 2019-10-15 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation
CA3084953A1 (en) * 2017-12-05 2019-06-13 Sunovion Pharmaceuticals Inc. Nonracemic mixtures and uses thereof
AU2020286441A1 (en) * 2019-06-04 2022-01-06 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001523241A (ja) * 1997-04-18 2001-11-20 サノフィ−サンテラボ 胃滞留性医薬組成物
WO2010023690A2 (en) * 2008-08-28 2010-03-04 Torrent Pharmaceuticals Ltd. Prolonged release formulation of amisulpride

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BR J CLIN PHARMACOL, vol. 83, JPN6024020027, 2017, pages 339 - 348, ISSN: 0005491782 *
INTERNATIONAL JOURNAL OF RESEARCH IN PHARMACY AND SCIENCE, vol. 2, no. 4, JPN6024020026, 2012, pages 48 - 60, ISSN: 0005491780 *
INTERNATIONAL RESEARCH JOURNAL OF PHARMACY, vol. 1, no. 1, JPN6024020029, 2010, pages 247 - 253, ISSN: 0005491781 *
REC RES SCI TECH, vol. 3, JPN6024020028, 2011, pages 32 - 36, ISSN: 0005333323 *

Also Published As

Publication number Publication date
WO2020247603A1 (en) 2020-12-10
EP3980008A4 (en) 2023-06-28
EP3980008A1 (en) 2022-04-13
US20220323409A1 (en) 2022-10-13

Similar Documents

Publication Publication Date Title
ES2935800T3 (es) Forma de dosificación oral de ketamina
US12161758B2 (en) Modified release formulations and uses thereof
JP2022535894A (ja) 放出調節製剤およびその使用
KR20210100667A (ko) 신경 또는 정신 장애의 치료 방법
JP2023103256A (ja) 非ラセミ混合物およびその使用
JP2012229261A (ja) 神経刺激性ステロイドの医薬組成物及びその使用
CA3059775A1 (en) Methods of treating developmental encephalopathies
AU2021263804A1 (en) Methods of use of T-type calcium channel modulators
CN101766626B (zh) 一种治疗精神分裂症的含布南色林的口服制剂
JP2003516347A (ja) 時間療法用ジルチアゼム製剤およびその投与法
EP4062906A1 (en) Oral pharmaceutical composition comprising carbamate compound and preparation method therefor
WO2012129759A1 (en) Oral dosage formulations containing both immediate-release and sustained-release drugs for treating neurodegenerative disorders
AU2018278967B2 (en) Pharmaceutical compositions of donepezil having specific in vitro dissolution profile or pharmacokinetics parameters
JP2022087834A (ja) 放出調節製剤およびその使用
HK40064212A (en) Modified release formulations and uses thereof
WO2023247665A1 (en) Solid dispersions of psilocybin
EP2961393A1 (en) Pharmaceutical compositions of donepezil having specific in vitro dissolution profile or pharmacokinetics parameters
HK40072206A (en) Oral pharmaceutical composition comprising carbamate compound and preparation method therefor
TW200815030A (en) Combination of a hypnotic agent and R (+)-α-(2,3-dimethoxy-phenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol and therapeutic application thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230605

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230605

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240521

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240528

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241224